DV
Dividend Vision

CSBR — Champions Oncology Inc

Champions Oncology Inc (CSBR)

Its deepest 1-year drawdown was 40.4%.

Champions Oncology is a technology-enabled research company that provides drug discovery and development solutions for the pharmaceutical and biotechnology industries, primarily through its Tumorgraft platform, which uses personalized cancer models, along with its Lumin Bioinformatics software for oncology research data. The company does not currently distribute dividends. Champions Oncology appeals to growth-oriented investors seeking exposure to oncology research services rather than income investors.

CSBR key facts

Asset type
Stock
Asset class
Equity
Inception date
11/29/1988
Last close
$5.07
Market cap
$85,126,248
Average volume
26300.0
Beta
0.389
Payout ratio
0.0
Forward P/E
22.8833
EPS
$-0.18